metaCDA: A Novel Framework for CircRNA-Driven Drug Discovery Utilizing Adaptive Aggregation and Meta-Knowledge Learning.

Journal: Journal of chemical information and modeling
PMID:

Abstract

In the emerging field of RNA drugs, circular RNA (circRNA) has attracted much attention as a novel multifunctional therapeutic target. Delving deeper into the intricate interactions between circRNA and disease is critical for driving drug discovery efforts centered around circRNAs. Current computational methods face two significant limitations: a lack of aggregate information in heterogeneous graph networks and a lack of higher-order fusion information. To this end, we present a novel approach, metaCDA, which utilizes meta-knowledge and adaptive aggregate learning to improve the accuracy of circRNA and disease association predictions and addresses the limitations of both. We calculate multiple similarity measures between disease and circRNA, construct a heterogeneous graph based on these, and apply meta-networks to extract meta-knowledge from the heterogeneous graph, so that the constructed heterogeneous maps have adaptive contrast enhancement information. Then, we construct a nodal adaptive attention aggregation system, which integrates a multihead attention mechanism and a nodal adaptive attention aggregation mechanism, so as to achieve accurate capture of higher-order fusion information. We conducted extensive experiments, and the results show that metaCDA outperforms existing state-of-the-art models and can effectively predict disease-associated circRNA, opening up new prospects for circRNA-driven drug discovery.

Authors

  • Li Peng
    School of Internet of Things Engineering, Jiangnan University, Wuxi 214122, China. pengli@jiangnan.edu.cn.
  • Huaping Li
    School of Computer Science and Engineering, Hunan University of Science and Technology, Xiangtan 411100, China.
  • Sisi Yuan
    Department of Bioinformatics and Genomics, the University of North Carolina at Charlotte, Charlotte, North Carolina 28223-0001, United States.
  • Tao Meng
    National Institute of Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention, Beijing 100050, China.
  • Yifan Chen
    Adam Smith Business School, University of Glasgow, Scotland, United Kingdom.
  • Xiangzheng Fu
  • Dongsheng Cao
    School of Pharmaceutical Sciences, Central South University, Changsha, China. oriental-cds@163.com.